[2014-Jan-08] FDA approves Farxiga to treat type 2 diabetes

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm380829.htm

farxiga.cdx

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl, Peggy J. McCann, Manorama Patel, Ravindar N. Girotra, Gang Wu, Philip M. Sher, Eamonn P. Morrison, Scott A. Biller, Robert Zahler, Prashant P. Deshpande, Annie Pullockaran, Deborah L. Hagan, Nathan Morgan, Joseph R. Taylor, Mary T. Obermeier, William G. Humphreys, Ashish Khanna, Lorell Discenza, James G. Robertson, Aiying Wang, Songping Han, John R. Wetterau, Evan B. Janovitz, Oliver P. Flint, Jean M. Whaley and William N. Washburn, Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes, J. Med. Chem., 2008, 51(5), 1145–1149

http://dx.doi.org/10.1021/jm701272q

Mona Ashiya & Richard E. T. Smith, Non-insulin therapies for type 2 diabetes, Nat. Rev. Drug Discov., 2007, 6(10), 777-778

http://dx.doi.org/10.1038/nrd2420

Edward C. Chao & Robert R. Henry, SGLT2 inhibition — a novel strategy for diabetes treatment, Nat. Rev. Drug Discov., 2010, 9(7), 551-559

http://dx.doi.org/10.1038/nrd3180

Ubiratan Fabres Machado & Maria Lucia Corrêa-Giannella, Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis, Expert Opin. Emerging Drugs, 2014, 19(1), 5-9

http://dx.doi.org/10.1517/14728214.2014.875530

William N Washburn, Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents, Expert Opin. Ther. Patents, 2009, 19(11), 1485-1499

http://dx.doi.org/10.1517/13543770903337828

André J Scheen, Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations, Expert Opin. Drug Metab. Toxicol., 2014, 10(5), 647-663

http://dx.doi.org/10.1517/17425255.2014.873788

Theodoros P. Angelopoulos & John Doupis, Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective, Adv. Ther., 2014, 31(6), 579–591

http://dx.doi.org/10.1007/s12325-014-0127-7

FDA approves first combination pill to treat hepatitis C

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm

harvoni.cdx

FDA approves Sovaldi for chronic hepatitis C

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm377888.htm

http://dx.doi.org/10.1074/jbc.M110.161802

Sofosbuvir.cdx

FDA approves Ofev to treat idiopathic pulmonary fibrosis

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418994.htm

http://dx.doi.org/10.1158/0008-5472.CAN-07-6307

Nintedanib.cdx

FDA approves Esbriet to treat idiopathic pulmonary fibrosis

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418991.htm

Pirfenidone.cdx